

## RESEARCH ARTICLE

# COVID-19 machine learning model predicts outcomes in older patients from various European countries, between pandemic waves, and in a cohort of Asian, African, and American patients



**Behrooz Mamandipoor<sup>1</sup>, Raphael Romano Bruno<sup>2</sup>, Bernhard Wernly<sup>3,4</sup>, Georg Wolff<sup>2</sup>, Jesper Fjølner<sup>5</sup>, Antonio Artigas<sup>6</sup>, Bernardo Bollen Pinto<sup>7</sup>, Joerg C. Schefold<sup>8</sup>, Malte Kelm<sup>2</sup>, Michael Beil<sup>9</sup>, Sviri Sigal<sup>9</sup>, Susannah Leaver<sup>10</sup>, Dylan W. De Lange<sup>11</sup>, Bertrand Guidet<sup>12,13</sup>, Hans Flaatten<sup>14</sup>, Wojciech Szczechlik<sup>15</sup>, Christian Jung<sup>16</sup><sup>2‡\*</sup>, Venet Osmani<sup>17</sup><sup>1‡</sup>**

**1** Digital Health Centre, Fondazione Bruno Kessler Research Institute, Trento, Italy, **2** Heinrich-Heine-University Duesseldorf, Medical Faculty, Department of Cardiology, Pulmonology and Vascular Medicine, Duesseldorf, Germany, **3** Department of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria, **4** Institute of General Practice, Family Medicine and Preventive Medicine, Paracelsus Medical University, Salzburg, Austria, **5** Department of Anaesthesia and Intensive Care, Viborg Regional Hospital, Viborg, Denmark, **6** Department of Intensive Care Medicine, CIBER Enfermedades Respiratorias, Corporacion Sanitaria Universitaria Parc Tauli, Autonomous University of Barcelona, Sabadell, Spain, **7** Department of Acute Medicine, Geneva University Hospitals, Geneva, Switzerland, **8** Department of Intensive Care Medicine, Inselspital, Universitätsspital, University of Bern, Bern, Switzerland, **9** Dept. of Medical Intensive Care, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel, **10** General Intensive care, St George's University Hospitals NHS Foundation trust, London, United Kingdom, **11** Department of Intensive Care Medicine, University Medical Center, University Utrecht, the Netherlands, **12** Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR\_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe: épidémiologie hospitalière qualité et organisation des soins, F-75012, Paris, France, **13** Assistance Publique—Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, France, **14** Department of Clinical Medicine, University of Bergen, Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway, **15** Jagiellonian University Medical College, Center for Intensive Care and Perioperative Medicine, Krakow, Poland

‡ These authors are joint senior authors on this work.

\* [Christian.Jung@med.uni-duesseldorf.de](mailto:Christian.Jung@med.uni-duesseldorf.de)

## OPEN ACCESS

**Citation:** Mamandipoor B, Bruno RR, Wernly B, Wolff G, Fjølner J, Artigas A, et al. (2022) COVID-19 machine learning model predicts outcomes in older patients from various European countries, between pandemic waves, and in a cohort of Asian, African, and American patients. PLOS Digit Health 1(11): e0000136. <https://doi.org/10.1371/journal.pdig.0000136>

**Editor:** Danilo Pani, University of Cagliari: Università degli Studi Di Cagliari, ITALY

**Received:** June 29, 2022

**Accepted:** September 26, 2022

**Published:** November 8, 2022

**Copyright:** © 2022 Mamandipoor et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Due to ethical reasons and institutional guidelines, the data presented in the study cannot be shared publicly. Data are available to researchers with some access restrictions applied upon request. Interested researchers may contact the corresponding author for more details.

**Funding:** The study was supported by a grant from Fondation Assistance Publique-Hôpitaux de Paris

## Abstract

## Background

COVID-19 remains a complex disease in terms of its trajectory and the diversity of outcomes rendering disease management and clinical resource allocation challenging. Varying symptomatology in older patients as well as limitation of clinical scoring systems have created the need for more objective and consistent methods to aid clinical decision making. In this regard, machine learning methods have been shown to enhance prognostication, while improving consistency. However, current machine learning approaches have been limited by lack of generalisation to diverse patient populations, between patients admitted at different waves and small sample sizes.

pour la recherche. The Health Region West also supported this study. EOSCsecretariat.eu provided support and has received funding from the European Union's Horizon Programme (grant agreement number: 831644); (H2020-INFRAEOSC-05-2018-2019). This work was supported by the Forschungskommission of the Medical Faculty of the Heinrich-Heine-University Düsseldorf, No. 2018-32 to G.W. and No. 2020-21 to RRB for a Clinician Scientist Track. The funders had no role in this work.

**Competing interests:** JCS report grants from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Dräger AG, Teleflex Medical GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, Phagenesis, and Nycomed outside the submitted work. The money was paid into departmental funds. No personal financial gain applied. The other authors declare no Competing Financial or Non-Financial Interests.

## Objectives

We sought to investigate whether machine learning models, derived on routinely collected clinical data, can generalise well i) between European countries, ii) between European patients admitted at different COVID-19 waves, and iii) between geographically diverse patients, namely whether a model derived on the European patient cohort can be used to predict outcomes of patients admitted to Asian, African and American ICUs.

## Methods

We compare Logistic Regression, Feed Forward Neural Network and XGBoost algorithms to analyse data from 3,933 older patients with a confirmed COVID-19 diagnosis in predicting three outcomes, namely: ICU mortality, 30-day mortality and patients at low risk of deterioration. The patients were admitted to ICUs located in 37 countries, between January 11, 2020, and April 27, 2021.

## Results

The XGBoost model derived on the European cohort and externally validated in cohorts of Asian, African, and American patients, achieved AUC of 0.89 (95% CI 0.89–0.89) in predicting ICU mortality, AUC of 0.86 (95% CI 0.86–0.86) for 30-day mortality prediction and AUC of 0.86 (95% CI 0.86–0.86) in predicting low-risk patients. Similar AUC performance was achieved also when predicting outcomes between European countries and between pandemic waves, while the models showed high calibration quality. Furthermore, saliency analysis showed that FiO<sub>2</sub> values of up to 40% do not appear to increase the predicted risk of ICU and 30-day mortality, while PaO<sub>2</sub> values of 75 mmHg or lower are associated with a sharp increase in the predicted risk of ICU and 30-day mortality. Lastly, increase in SOFA scores also increase the predicted risk, but only up to a value of 8. Beyond these scores the predicted risk remains consistently high.

## Conclusion

The models captured both the dynamic course of the disease as well as similarities and differences between the diverse patient cohorts, enabling prediction of disease severity, identification of low-risk patients and potentially supporting effective planning of essential clinical resources.

## Trial registration number

NCT04321265.

## Author summary

COVID-19 remains a complex disease, making it challenging to estimate the risk of deterioration of critically ill patients and consequently allocation of clinical resources, such as ventilators. As a result, there is a need to support clinical decision making through objective methods and address some of the limitations of the current clinical scoring systems. In response, we developed machine learning models using routine clinical data of patients from 37 countries worldwide, including 18 European countries. We find that: i) machine

learning models can predict outcomes in patients from diverse European countries, that is which patients have a low risk of deterioration and which may require increased care such that resources are allocated efficiently; ii) routine clinical data from European patients can be used to predict outcomes in non-European patients, namely those admitted in Asian, African, and American intensive care units, without significantly affecting the performance, and iii) routine clinical data collected during the first COVID-19 pandemic wave, can be used to predict the risk of deterioration of patients admitted during subsequent waves. Our study is the first step towards improving standardisation and equity of critical care across healthcare institutions and further afield across diverse countries and territories.

## Introduction

The coronavirus pandemic continues to strain health care systems globally [1]. While much has been discovered about the disease aetiology, many open questions remain around disease trajectories, considering diverse patient outcomes in terms of mortality rate as well as the need for ventilation. Several studies [2–4] have found that 3% to 79% of hospitalised patients required invasive mechanical ventilation (MV), with a significant heterogeneity in ICU outcomes [5]. These aspects render clinical resource allocation challenging to plan. Early risk stratification can help in early identification of patients with a high risk of deterioration and adjust treatment course. However, varying symptomatology, especially pronounced in older patients, still includes several unknowns. Furthermore, the current scoring systems in clinical practice are limited by small sample size and consequently have low predictive power, especially for prediction of mortality in COVID-19 patients [6].

More objective and consistent methods are required that can assist clinicians in discriminating between patients with low risk of deterioration and those that may require increased care, estimating risk in a continuous manner considering evolution of the patients' state as well as administration of therapeutical interventions. Assisting clinicians in this manner becomes crucial for countries with limited resources and varying expertise, especially facing a novel disease (such as COVID-19) where reliable models to guide effective allocation of essential resources and improve patient outcomes are scarce [7]. Furthermore, more objective assessment methods have the potential to mitigate inequalities in allocation of medical resources [8,9].

Machine learning approaches have shown the potential to enhance prognostication, by capturing non-linear relationships between variables to predict outcomes of interest. However, current efforts have been limited by lack of generalisation to diverse patient populations, between patients admitted at different waves and small sample sizes. While there are many studies investigating prediction of outcomes in COVID-19 patients [10–14], only a handful have investigated generalisability of the models across countries with diverse populations located in different continents using imaging [15] and no studies have been found that used routinely collected data, as outlined in [15]. Indeed, a recent review on chest imaging, emphasised the importance of validation dataset to assess generalisability of the model to other cohorts, rather than only on the sampled population [16].

Therefore, the main objective of this work is to investigate whether the use of routinely collected Electronic Health Records (EHR) data in older patients with COVID-19, coupled with machine learning (ML) algorithms can generalise to diverse patients' populations, to estimate the risk of ICU and 30-day mortality, as well as identify patients at low risk of deterioration,

likely to survive without a therapeutic intervention. We hypothesised that a machine learning model derived in a cohort of COVID-19 older patients can be used to predict clinically relevant outcomes of both, geographically and temporally (between pandemic waves) diverse cohorts.

## Methods

To address our hypothesis, we developed and validated several machine learning models, derived from data collected from 3,933 older patients with a confirmed COVID-19 diagnosis, admitted to ICUs located in 37 countries, between January 11, 2020, and April 27, 2021 as part of the COVIP study (trial registration number NCT04321265, March 25, 2020). We evaluate the resulting models in a i) *retrospective study* with validation between the European countries to assess inter-country generalisability of the European model; ii) *prospective study* between the pandemic waves to evaluate the ability of the model derived from a cohort of patients admitted during a COVID-19 wave to generalise in predicting outcomes in patients admitted to European ICUs during the subsequent wave; and iii) *external validation* in a cohort of non-European patients, to evaluate whether the model derived from the overall European cohort can be used to predict outcomes in highly diverse patients, such as those admitted to Asian, African and American ICUs.

For each of the three study designs, we investigated whether the models' predicted probabilities match the actual observed probabilities of each of the three outcomes, namely quality of the model calibration. We also performed saliency analysis to identify the top-ranked variables that contributed most to the prediction of each of the three outcomes of interest for each study design.

## Outcomes definition


Primary outcomes in this study were: 1) mortality prediction, either in the ICU or 30 days after ICU admission; and 2) early identification of patients at low risk of deterioration, defined as patients who survived in the ICU without receiving any therapeutic intervention (i.e. invasive or non-invasive mechanical ventilation, administration of vasopressors, renal replacement therapy, and tracheostomy).

## Study design

Our analysis primarily focuses on the European patient cohort, while we used the non-European cohort as the external validation dataset to investigate the generalisability of the models when encountering diverse patient populations, such as those from different continents. The overall workflow and study design is depicted in Fig 1.

Initially, we retrospectively assessed the generalisability of the models among the European cohort, evaluating the predictive performance of the models derived from 16 European countries (as shown in Fig 2) using the patient cohort from France (that had the highest number of ICU admissions) as the validation. Furthermore, we evaluated inter-country generalisability of the European model, by evaluating its performance on top-nine European countries (based on the highest number of ICU admissions) separately, each time deriving the model from the patient cohorts of the remaining countries, in a leave one country out approach.

Following from this, we prospectively assessed the temporal generalisability of the models between different waves, by deriving a model from a patient cohort admitted before December 1<sup>st</sup>, 2020 (our cut-off date) and validating in a cohort of patients admitted on or after December 1<sup>st</sup>, 2020. The cut-off date was chosen based on the availability of the data as well as peak of




**Fig 1.** Description of variables, algorithms, and outcomes as well as pre-processing steps for the overall dataset (panel A). Retrospective validation of the model derived on the European cohort based on cross-validation as well as external validation on France as the country with highest ICU admissions (panel B), while the results for the rest of the European countries are shown in Tables A-C in S6 Text. Prospective validation of the model derived on the European cohort of patients admitted to ICUs before the cut-off date (December 1st, 2020) and validated on the European cohort of patients admitted to ICUs after the cut-off date, during the subsequent pandemic wave (panel C). External validation of the model derived on the overall European cohort and validated on the cohort of patients admitted to Asian, African and American ICUs (panel D). Note, EU is an abbreviation of Europe.

<https://doi.org/10.1371/journal.pdig.0000136.g001>

cases per million in Europe between the first wave (peaking on November 7<sup>th</sup>, 2020) and the subsequent wave (peaking around January 11<sup>th</sup>, 2021) as shown in Fig C in [S2 Text](#).

Lastly, we externally evaluated the predictive performance of the models derived from the overall European patient cohort to assess their generalisability in a validation cohort of patients admitted to Asian, African, and American ICUs.



**Fig 2.** Map of the countries and continents represented in our dataset (left panel). Number of patients for the overall cohort as well as mortality rate per country (right panel). Country and territory abbreviations are detailed in [S9 Text](#). (Map created with QGIS v.3.26 based on data from Natural Earth).

<https://doi.org/10.1371/journal.pdig.0000136.g002>

For each study design we defined three outcomes of interest, namely ICU mortality, 30-day mortality and identification of low-risk patients. For the internal evaluation of each study design, namely of the European cohort leaving out France, European cohort admitted before the cut-off date December 1st, 2020, and the overall European cohort, we used stratified 5-fold cross-validation with 10 times repetition, starting with different initial random states to mitigate the randomness effects of a single train-test split.

### Ethics approval and consent to participate

The study was approved by the Ethics Committee of the University of Duesseldorf, Germany. Institutional research ethic board approval was obtained from each study site, as a prerequisite for participation in the study.

### Clinical data sources and settings

The study included older patients (over 70 years) admitted to ICUs originating from 37 countries around the world, with a confirmed diagnosis of COVID-19 based on a positive polymerase chain reaction (PCR) test. National coordinators of the study oversaw ICUs recruitment, obtaining national and local ethical approval, and supervising patient recruitment. Ethical approval was mandatory to participate in the study. The study was in line with the European Union General Data Privacy Regulation (GDPR) directive as part of the multi-centre COVIP clinical trial (ID: NCT04321265), where a database was established to facilitate the information sharing of electronic case report forms (eCRF) of each subject on a secure server at the Aarhus University, Denmark.

### Study population

All the patients involved in this study were at least 70 years old, admitted to 217 different ICUs from 172 cities in 37 independent countries between January 11, 2020, and April 27, 2021. The dataset included overall 3,933 patients with a unique eCRF record since each patient could only be entered into the database once regardless of their transfer to another ICU or readmission. After applying the selection criteria 3,474 patients remained, out of which 2,858 patients were admitted in European ICUs, while 616 patients were admitted in Asian, African and American ICUs. Patients were excluded due to having negative sarscov2 test and significant missing information, as shown in selection criteria diagram in [S8 Text](#). All patients were followed up through a phone interview for their survival status after 30-days and 3-months from the ICU discharge.

### Study data and variables of interest

All the participating centres reported the patients' information using consistent electronic case report forms (eCRF). Collected demographic information included age, sex, height, weight, and BMI. Furthermore, information about the presence of symptoms before hospitalization and the duration of hospital stays before ICU admission were also recorded.

Sub-scores of sequential organ failure assessment (SOFA): respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems were calculated at the ICU admission. Six different pre-existing comorbidities were also documented in eCRF form: diabetes, ischemic heart disease, renal insufficiency, arterial hypertension, pulmonary comorbidity, and congestive heart failure. The definitions of these comorbidities are available in [S1 Text](#).

Several laboratory measurements were also retrieved for the patients during their ICU admission. The partial pressure of oxygen (PaO<sub>2</sub>) and the fraction of inspired oxygen (FiO<sub>2</sub>)

were recorded based on the first arterial blood gas (ABG) analysis. The highest measured values of serum bilirubin, serum creatinine, c-reactive protein, and leukocytes count were documented on admission day. The serum lactate concentration was reported on both the first and second days of ICU admission separately. Furthermore, the minimum available measurements of thrombocyte count and lymphocyte count were also recorded.

Information on drug therapy during patients' ICU stays included antibiotics, corticosteroids, and antiviral drugs, while also documenting bacterial co-infection. Finally, therapeutic interventions including invasive and non-invasive ventilation, vasopressor use, renal replacement therapy, tracheostomy, as well as their day of occurrence after ICU admission were also available in the dataset.

### Statistical analysis

We analysed baseline characteristics of patients using medians (IQRs) for continuous variables and frequencies (percentages) for categorical variables. We used the Kruskal–Wallis test (ANOVA) for continuous variables and the chi-square test for categorical variables to compare subgroups of alive and deceased patients.

### Data preparation

After removing inconsistently recorded information, we standardised variables into unique measurement units. For example, we converted PaO<sub>2</sub> values with kilopascals (kPa) to millimetres of mercury (mmHg). Then we transformed ICU length of stay, mortality time and intervention start time into daily units. We converted textual notes of drug usage into binary variables indicating whether a drug was administered. We also extracted the SOFA sub-scores for each patient from their textual clinical notes and converted them to 6 separate variables with values ranging from 0 to 4. However, in the case of an incorrectly reported text, they were considered as missing values. We also checked the total SOFA score for consistency, summing all the sub-scores.

To improve interpretability, we defined four clinically meaningful intervals for each intervention, namely 0 to 2 days, 3 to 6 days, 7 to 30 days, and after 30 days, which then became separate binary variables. Furthermore, to mitigate the effect of noisy data and outliers in the dataset, we defined clinically valid intervals for the relevant variables and those variables outside of the intervals were considered as missing values. Since machine learning models typically cannot handle missing data, we imputed the missing information of patients in the dataset in several steps. We considered unreported values of bacterial co-infections and those reported as “unknown” as missing values. Then, we used the median for continuous and mode for categorical variables to impute the missing values in the rest of the dataset. Finally, we transformed each continuous variable individually within a zero to one range, maintaining their distribution, while we encoded the rest of the categorical variables using the one-hot encoding scheme.

To mitigate potential data leakage during the model derivation and validation, all the pre-processing steps were conducted after the data was split in train-test sets. Consequently, during the internal 5-fold cross-validation experiment design, the patients were divided into training folds and test folds first, and only then all the transformation steps were applied over the data. Furthermore, we excluded variables indicating clinical therapeutic interventions after 30 days for the 30-day mortality prediction outcome; and excluded all the variables that indicated therapeutic intervention when predicting the low-risk outcome. We also used the 3-month outcome to ensure consistency of the primary outcome and allay the concerns of censoring bias.

## Model development and validation

During model development we compared the performance of three algorithms, namely, Extreme Gradient Boosting (XGBoost) [17] as the primary model with Feed-Forward (FF) neural network and Logistic Regression (LR) [18] to predict ICU mortality, 30-days mortality after ICU admission, and low-risk patients admitted to the ICU. XGBoost is an ensemble of decision trees that provides robust predictive performance with learning complex and non-linear relationships in data using an ensemble learning technique called boosting. Boosting is an iterative learning process, sequentially building many models that correct the deficiencies of the preceding model. Even though deep neural networks provide better predictive performance in unstructured datasets, XGBoost has shown great predictive performance for structured, tabular data [19].

To compare the performance of XGBoost, we also implemented Feed-Forward as a deep neural network and Logistic Regression as a statistical baseline competitor. Feed-Forward model was a two-layer neural network with 64 and 16 neurons in the first and second layer respectively, using sigmoid activation function. Model parameters were randomly initialized based on Xavier normal method, trained for 100 epochs with batch size 32, and optimized using the Adam optimizer algorithm. Logistic Regression is a statistical method, investigates the relation of the outcome variable with the input variables, and typically considered as a baseline algorithm in clinical classification tasks.

All the three models were tuned for the best hyperparameters on the internal evaluation cohorts in each study design and outcome definitions. The models' hyperparameters were optimized through exhaustive grid-search for maximizing the F-1 score metric and set for the final internal and external evaluation.

## Experimental evaluation

Training and evaluation of the models was based on 5-fold stratified cross-validation with 10-times repetition starting with different random states. Stratification ensures that outcome distribution in each fold is representative of the distribution of outcomes across the entire study population. Predictive performance of the models was evaluated using area under the receiver operator characteristic curve (AUC) and area under the precision-recall curve (AUPRC). Furthermore, since machine learning models can be discriminative but with low calibration quality, the calibration curve was plotted for all the analyses. The calibration curve shows the actual class probabilities against the models' probability predictions and is evaluated using Brier scores (a lower Brier score indicates higher calibration quality). To assess the predictive performance, additional metrics were also calculated, including Positive Predictive Value (PPV), Negative Predictive Value (NPV), F-1 score, and Matthews correlation coefficient (MCC), shown in S4 Text. We note that in addition to MCC that considers the class imbalance [20], other methods could also be applicable, such as partial AUC [21] or subgroup analysis [22].

## Model interpretation

We used SHAP (Shapley Additive exPlanations) to interpret the output of the predictive models [23]. SHAP is a powerful method that explains how the model makes individual predictions by deconstructing every prediction into the sum of contributions from each input variable, known as SHAP values. SHAP values are a game-theoretic approach to model interpretability revealing how the input variables influence the final model's predictions at the instance level and throughout the entire population.

In this study a SHAP value was calculated for each run of the 5-fold cross-validation (repeated 10 times) to precisely capture the influence of each variable during the model evaluation. These values were then plotted into a Bee swarm plot, an informative display of SHAP values that shows the relative importance of variables and their actual relationships with the predicted outcome.

## Results


### Study population

The overall dataset contained 3,933 electronic health records of patients, out of which 3,474 patients remained after applying the exclusion criteria as shown in the cohort selection diagram in [S8 Text](#). The final cohort contained patients originating from 37 different countries (17 European and 20 non-European), admitted to ICUs between January 11, 2020, and April 27, 2021, shown in [Fig 2](#).

The European cohort included 2,858 patients with an average mortality rate of 45% both in ICU and 30 days after ICU admission, while 13% of patients were at low risk of deterioration. European patients' age median was 75 years (IQR, [72–78]), with 30% female, and median length of ICU stay was 13 days (IQR, [6–22]). The distribution of patients among the European countries, including the number of patients as well as ICU mortality rate per country is shown in [Fig 3](#), while the distribution of length of stay and mortality is shown in Figs A and B in [S2 Text](#) respectively.


France was chosen as the validation cohort to assess the generalisability among the European cohort because it had the highest number of patients in the database (647, or 22% of the European cohort), with 40% mortality rate (ICU and 30-day) and 19% of patients with a low risk of deterioration. Furthermore, we also evaluated generalisability of the European predictive model on a per-country basis using leave one country out approach. Namely, we selected nine European countries with the highest number of ICU admissions and separately evaluated each corresponding cohort on the model derived from the remaining European countries as shown in [S6 Text](#).

We prospectively evaluated temporal generalisability of our European model using a cohort of 715 (25%) patients admitted to ICU after December 1st, 2020, with a median age of 75 years



**Fig 3.** Distribution of patients admitted to European ICUs as a percentage (%) of the overall European cohort (left panel). Number of patients admitted to European ICUs as well as the mortality rate per European country, shown as a ratio between survivors (blue) and non-survivors (grey) (right panel). Country and territory abbreviations are detailed in [S9 Text](#).

<https://doi.org/10.1371/journal.pdig.0000136.g003>



**Fig 4.** Distribution of patients admitted to non-European ICUs as a percentage of the overall non-European cohort (left panel). Number of patients admitted to non-European ICUs as well as the mortality rate per non-European country, shown as a ratio between survivors (blue) and non-survivors (grey) (right panel). Country and territory abbreviations are detailed in S9 Text.

<https://doi.org/10.1371/journal.pdig.0000136.g004>

(IQR, [72–79]), median ICU length of stays 11 days (IQR, [6–20]) and having 32% female patients. The model was derived in a cohort of 2,143 patients with a median age of 75 years (IQR, [72–78]), median ICU length of stay of 14 days (IQR, [8–23]) and having 28% female patients.

Mortality rate in the ICU and 30-day for the derivation cohort (up to cut-off date of December 1<sup>st</sup>, 2020) was 41% and 42% respectively. However, after the cut-off date it increased to 55% and 52% posing a significant challenge for model generalisability. Rate of low-risk patients admitted to ICUs remained at a similar rate of 13% for both cohorts.

Finally, the non-European cohort contained 616 patients that had higher ICU and 30-day mortality at 54% in comparison to the European cohort as well as higher rate of low-risk patients admitted to ICU at 25%. Also, the median age of the non-European cohort was 76 years (IQR, [73–81]), with 40% patients female, and the median duration of ICU stay of 7 days (IQR, [4–10]). Detailed information of patient distribution among the non-European countries with a summary of the ICU mortality rate and the number of patients per country are visualised in Fig 4 while the distribution of length of stay and mortality is shown in Figs A and B in S2 Text respectively.

Shown in Table 1 are the detailed characteristics of patients of European and non-European cohorts based on the ICU mortality, while the patient characteristics for the 30-day mortality and low-risk patients are shown in Tables A and B in S7 Text respectively.

## Performance evaluation

All the three algorithms showed similar performance during the evaluation of the model derived in the European cohort (excluding patients admitted to French ICUs) and validated on the French patient cohort. Although, XGBoost had a higher performance with AUC of 0.82 (95% CI 0.82–0.82), 0.79 (95% CI 0.79–0.79) and 0.86 (95% CI 0.86–0.87), for the three outcomes, indicating a high generalisability of the model as shown in Fig 5. XGBoost showed highest performance also in terms of Average Precision (AP), as well as calibration quality (lowest Brier score) shown in Figs D–F in S3 Text. Additional performance metrics including positive and negative predictive value (PPV and NPV), F-1 score and Matthews correlation coefficient (MCC) are shown in S4 Text. Furthermore, we also assessed per country


**Table 1.** Patient characteristics of the European and the non-European cohort, based on ICU mortality outcome. Patient characteristics for the two other outcomes of interest, namely 30-day mortality and early identification of patients at low risk of deterioration are available in Tables A and B in S7 Text respectively.

ICU	European			non-European		
	Variables	Alive	Dead	p-value	Alive	Dead
Patients (%)	1574 (0.55)	1284 (0.45)	-	284 (0.46)	332 (0.54)	-
Age (year)	74 [72,78]	75 [72,79]	<0.001	75 [72,80]	77 [73,83]	0.003
Sex (Female)	477 (30.3)	350 (27.3)	0.081	115 (40.5)	129 (38.9)	0.74
Weight (kg)	80 [72,90]	80 [72,90]	0.313	78 [70,89]	78 [70,87]	0.621
Height (cm)	170 [165,178]	170 [165,177]	0.162	165 [159,170]	166 [160,173]	0.195
BMI	27.6 [24.8,30.9]	27.5 [24.7,30.8]	0.894	27.9 [24.9,33.2]	28.3 [25.6,31.1]	0.737
SOFA overall score	4 [3,7]	6 [4,9]	<0.001	4 [2,5]	7 [5,10]	<0.001
Presence of diabetes	490 (31.2)	462 (36.2)	0.006	156 (55.1)	187 (56.8)	0.73
Ischemic heart disease	318 (20.4)	308 (24.3)	0.015	78 (27.7)	92 (28.6)	0.875
Renal comorbidity	193 (12.3)	255 (20.0)	<0.001	29 (10.3)	80 (24.5)	<0.001
Arterial hypertension	1029 (65.6)	857 (66.9)	0.484	174 (61.5)	233 (71.3)	0.014
Pulmonary disease	341 (21.7)	301 (23.6)	0.241	47 (16.6)	59 (18.4)	0.642
Congestive heart failure	203 (13.0)	205 (16.2)	0.019	33 (11.8)	48 (14.8)	0.34
Mechanical ventilation	979 (62.2)	1142 (88.9)	<0.001	69 (24.3)	271 (81.6)	<0.001
Vasopressors	936 (59.5)	1146 (89.3)	<0.001	38 (13.4)	184 (55.4)	<0.001
Renal replacement therapy	150 (9.5)	317 (24.7)	<0.001	16 (5.6)	52 (15.7)	<0.001
Non-invasive ventilation	412 (26.2)	340 (26.5)	0.888	74 (26.1)	156 (47.0)	<0.001
Tracheostomy	350 (22.2)	241 (18.8)	0.026	15 (5.3)	13 (3.9)	0.537
ICU length of stay (day)	12 [6,26]	14 [7,22]	0.097	6 [3.8,10]	7 [4,11]	0.293

<https://doi.org/10.1371/journal.pdig.0000136.t001>


generalisability of our model by evaluating its performance on the nine European countries (with the highest number of ICU admissions) separately, each time deriving the model from the patient cohorts of the remaining countries, in a leave one country out approach. The results of these analyses are shown in Tables A-C in S6 Text for each of the outcomes.

In the prospective evaluation of the model on the cohort of European patients admitted after the cut-off all three algorithms showed a similar performance in predicting 30-day mortality with AUC of 0.77 (95% CI 0.77–0.77), while XGBoost was superior in predicting ICU mortality with AUC of 0.83 (95% CI 0.83–0.83). In predicting low-risk patients, both FF and XGBoost showed similar performance with AUC of 0.85 (95% CI 0.85–0.85). Performance of



**Fig 5. AUC performance of each model in validation on patients admitted in ICUs in France as the country with the highest number of ICU admissions for each of the three outcomes.** AUC and AUPRC performance graphs of each model in internal cross-validation are available in Fig A in S3 Text.

<https://doi.org/10.1371/journal.pdig.0000136.g005>



**Fig 6.** AUC performance of each model in the European cohort of patients admitted to ICUs after the cut-off date of Dec 1st, 2020 for each of the three outcomes. AUC and AUPRC performance graphs of each model in internal cross-validation are available in Fig B in S3 Text.

<https://doi.org/10.1371/journal.pdig.0000136.g006>

each algorithm in terms of AUC is shown in Fig 6, while detailed performance metrics are shown in S4 Text.


Lastly, in the external validation of the European model in a cohort of Asian, African, and American patients, XGBoost achieved AUC of 0.89 (95% CI 0.89–0.89) for ICU mortality, AUC of 0.86 (95% CI 0.86–0.86) for 30-day mortality prediction, and AUC of 0.86 (95% CI 0.86–0.86) in predicting low-risk patients as shown in Fig 7. Furthermore, our results showed that majority of the models are well calibrated as shown from the reliability curves in S3 Text as well as Brier scores in S4 Text.

### Model interpretation and variable importance ranking

This study evaluated three models over three different population study designs with three different outcomes of interest. However, for the analysis of variable importance and model interpretation, we focus on the best performing model, the XGBoost.


We applied SHAP method over the models' prediction during each cycle of the 5-fold cross-validation with the 10-times repetition. Unlike the typical approaches in the literature that apply SHAP at the final model only, our approach allows us to investigate predictive impact of each variable much more thoroughly and spot any inconsistencies with the final results. The Beeswarm plots shown in Fig 8 present the relative importance of the top 10 variables and their actual relationships with the predicted outcomes, while the calculated average of absolute SHAP value for each of the ranked variables is available in Fig A in S5 Text.

Vasopressor use and mechanical ventilation within the first 2 days of ICU admission had the highest impact on ICU mortality prediction, followed by the FiO<sub>2</sub> and age, for both internal and external cohorts. These two variables were also highly important for the prediction of



**Fig 7.** AUC performance of the model derived from the overall European cohort and externally validation in a cohort of Asian, African, and American patients for each of the three outcomes. AUC and AUPRC performance graphs of each model in internal cross-validation are available in Fig C in S3 Text.

<https://doi.org/10.1371/journal.pdig.0000136.g007>




**Fig 8.** SHAP summary plots showing the top-10 most important variables for each of the three outcomes of interest, when evaluating the European model internally (left) as well as externally on the non-European cohort (right). Colour represents the actual value of the variables (red indicating higher values), while the higher the SHAP value of a variable (depicted in the x-axis), the higher the estimated probability of the outcome. For some variables we also indicate the interval of occurrence, for example “Vasopressors (0–2)” indicates administration of vasopressors during the first 2 days from the admission.

<https://doi.org/10.1371/journal.pdig.0000136.g008>

30-day mortality in the European and non-European cohorts, while tracheostomy was highly predictive for patients' survival only in the European cohort. In identifying patients at low risk of mortality, all the 10 highest ranked variables were similar in both the European and the non-European cohorts, with SOFA and its' sub-scores emerging as the strongest predictive factors.

In addition to the importance of the overall variables, we sought to also investigate the values of individual continuous variables and their association to the predicted risk of outcome. From these analyses, shown in Fig 9, the predicted risk of ICU mortality gradually increases with age until around 80 years, beyond which remains high. Predicted 30-day mortality shows a similar pattern, although the age threshold appears to be slightly higher, at around 85. FiO<sub>2</sub> values of up to 40% do not appear to increase the predicted risk of ICU and 30-day mortality, while PaO<sub>2</sub> values of 75 mmHg or lower are associated with a sharp increase in the predicted risk of ICU and 30-day mortality. Lastly, increase in SOFA scores, gradually augment the predicted risk of deterioration (as would be expected), however only up to a threshold value of 8, where beyond these SOFA scores the predicted risk remains consistently high. Very low values




**Fig 9.** Dependency plots outlining relationship between the actual values of the variables (x-axis) and risk of predicted outcome (y-axis) expressed in terms of SHAP values. Higher SHAP values are associated with an increase in the risk of the outcome and vice-versa. For example, increasing age (x-axis in the top left graph), gradually increases the risk of predicted ICU mortality up to around 80 years. Beyond this value, the risk remains high. These results pertain to the model derived on the overall European cohort and validated externally on the non-European cohort. Values of FiO<sub>2</sub> are expressed in percentages and PaO<sub>2</sub> in mmHg, while leucocytes and thrombocytes are in million per microliter (x 10<sup>9</sup>/μL).

<https://doi.org/10.1371/journal.pdig.0000136.g009>

of leucocytes (below  $4.5 \times 10^9/\mu\text{L}$ ) and those above  $11 \times 10^9/\mu\text{L}$  appear to increase the predicted risk of deterioration, however the picture is less clear cut for values beyond this range as there is a high variability between the patients. Low values of thrombocytes, below  $100 \times 10^9/\mu\text{L}$  appear to increase the predicted risk of deterioration, but only in a fraction of the patients, while the predicted risk appears to be decrease above this value.

Furthermore, considering that the starting day of intervention had a significant impact on the predicted mortality, we sought to investigate the differences between the patients that survived in the ICU and those that did not, in terms of days when various interventions were administered during the ICU stay. As can be seen from Fig 10 patients that did not survive had Renal Replacement Therapy administered more often during the first week of stay (bottom graph, dark blue) than the patients that survived (top graph, light blue). Furthermore, for patients that survived, tracheostomy was administered more often in comparison to patients that did not survive. In terms of the other types of interventions, namely mechanical and non-invasive ventilation as well as vasopressors, we did not find significant differences in our dataset.



**Fig 10. Differences between patients that survived in the ICU and those that did not, in terms of frequency of interventions administered in a particular day during their ICU stay, in the European cohort.** Shade of colour represents the frequency of administration for the overall European cohort. The darker the shade, the more patients were administered a particular intervention on that specific day. White boxes represent no recorded interventions for that day.

<https://doi.org/10.1371/journal.pdig.0000136.g010>

## Discussion

This is one of the first studies to demonstrate high performance generalisability (AUC up to 0.86) of machine learning models in predicting clinically relevant outcomes of older patients from diverse patient populations with COVID-19, including patients from different European countries, across different continents and ethnicities, as well as patients admitted in different COVID-19 waves.

While there have been several previous studies that have investigated feasibility of machine learning for predicting deterioration and mortality of COVID-19 patients [10–13] including resource allocation [14], none of the studies have evaluated generalisability across highly geographically diverse patient populations [7].

Furthermore, this level of generalisability performance was achieved using only routinely collected clinical and demographic variables, suggesting the applicability of our method also in low-end equipped ICUs and healthcare institutions.

Achieving high generalisability with diverse patient populations is important since availability of this type of model, especially in countries with limited resources and expertise could become an important decision-making aid, lending objective support to the complex issue of resource allocation. These models might prove particularly important in patients, where the best course of therapeutic action is difficult to judge at the admission due to disease complexity or lack of prior expertise when facing a novel disease.

To further aid decision making we performed saliency analysis on our model such that clinicians can identify patients at low risk of deterioration, and consequently the care and resources can be prioritised as early as possible. Our findings are consistent with previous studies highlighting importance of clinical markers such as age and oxygen saturation. However, while we find that SOFA is a good predictor of estimating patients at low risk, it becomes less important in mortality prediction, which our model estimates principally through age, and FiO<sub>2</sub> variables. This finding is in line with the previous work, which found poor discriminant accuracy of the SOFA score for mortality prediction [6,24].

Our model also captured the association between increased risk of mortality and administration of vasopressors and mechanical ventilation within the first 48 hours after the admission, as shown in Fig 8. In the same line, performing tracheostomy after the first week of admission increased the risk of 30-day mortality, but not of ICU mortality.

While patients' age increases the risk of mortality, this appears true only until a threshold of 80 years, after which the risk of ICU mortality remains high. Similarly values of FiO<sub>2</sub> up to 40% do not appear to increase the risk of estimated ICU and 30-day mortality, while an increase in SOFA scores increase the estimated risk of deterioration, but only up to the score of 8. Beyond this SOFA score the risk remains high, as shown in Fig 9. Finally, very low values of leucocyte count (below  $4 \times 10^9/\mu\text{L}$ ) increase the estimated risk of deterioration and the same is true for low values of thrombocytes (below  $100 \times 10^9/\mu\text{L}$ ), but only in a fraction of the patients for the latter.

Majority of the previous studies utilised only admission data to predict the risk of a single event, while typically not considering the subsequent therapeutical interventions, except for the work in [25] that focused on prediction of favourable outcomes and in [26] that focused on predicting the need for mechanical ventilation, validating their models within a patient population from a single country. One of the advantages of our methodology is that our predictive model can generate continuous risk prediction scores, taking into consideration also therapeutical interventions, such as vasopressors or mechanical ventilation, in updating risk estimation. Moreover, we have shown that the continuous risk estimation can be applied to highly diverse patient populations.

Many design and implementation decisions of our work have been made with a future clinical practice deployment in mind. In this respect, geographical and temporal evaluation of the model as well as continuous risk prediction would be important steps in understanding performance of the model in a clinical practice. Furthermore, our models are not only interpretable in terms of importance of variables based on SHAP values, but we also provide specific cut-off points for some of the variables where the risk of outcome increases significantly, building upon our previous work [24].

These results show that our model derived from a cohort of European patients can be used to predict outcomes of interest in patients admitted to non-European ICUs, rendering it particularly relevant for countries where essential resources (such as ventilators) might be scarce, with varying availability of clinical expertise. From this analysis we believe that our model can support physicians in estimating prognosis and therapy course. However, this model should be seen as an additional tool that supports clinical decision making as part of a holistic patient assessment, while the final decision rests with the judgement of the clinicians, especially considering ethical issues [27,28].

## Limitations

The present study has some methodological limitations in common with the other COVIP-studies [29–33], such as COVIP does not contain a control group of younger COVID-19

patients for comparison, or a comparable age cohort of ICU / non-ICU patients. In addition, the COVIP database does record information on time from symptoms onset to ICU admission. These treatment limitations might also affect the care of older ICU patients. Furthermore, COVIP recruited patients in many countries with a wide variety in their care structure, resulting in a considerable heterogeneity of treatments.

## Conclusions

This study demonstrates that even in the case of very diverse COVID-19 patients from other countries and continents, machine learning methods can generalise well and produce precise risk estimates to support clinical decision making. Our models captured both the dynamic course of the disease by including occurrence and time-to-event information of clinical events as well as similarities and differences between the diverse cohorts, allowing prediction of disease severity, identification of low-risk patients and potentially supporting effective planning of essential intensive care resources.

## Supporting information

**S1 Text. Definition of comorbidities.**  
(DOCX)

**S2 Text. Distribution of length of stay and mortality for the European and non-European cohorts as well as difference between COVID-19 waves.**  
(DOCX)

**S3 Text. Performance for Area Under the ROC curve, Precision Recall curve as well as model calibration analysis for internal, prospective, and external validation cohorts for each of the outcomes of interest.**  
(DOCX)

**S4 Text. Detailed performance metrics, including Average Precision, Positive and Negative Predictive Value, F-1 score, Mathews Correlation Coefficient as well as Brier calibration score, for the internal, prospective, and the external validation cohorts for each of the outcomes of interest.**  
(DOCX)

**S5 Text. Variable ranking for the European and non-European cohort for each of the three outcomes of interest.**  
(DOCX)

**S6 Text. Evaluation of generalisability of the model derived on the European cohort using each of the top-9 European countries (based on the number of ICU admissions) as the test cohort.**  
(DOCX)

**S7 Text. Patients' characteristics, including differences between the full set of variables, for the European and non-European cohort with respect to the three outcomes of interest (ICU and 30-day mortality and prediction of low-risk patients).**  
(DOCX)

**S8 Text. Cohort selection diagram.**  
(DOCX)

**S9 Text. Abbreviations of the countries and territories.**  
(DOCX)

## Acknowledgments

The authors acknowledge the contributions from the members of the COVIP study group. Furthermore, the authors acknowledge Maurizio Napolitano's help with the World map in [Fig 2](#).

## Author Contributions

**Conceptualization:** Behrooz Mamandipoor, Christian Jung, Venet Osmani.

**Data curation:** Behrooz Mamandipoor, Bernhard Wernly, Christian Jung, Venet Osmani.

**Formal analysis:** Behrooz Mamandipoor, Raphael Romano Bruno, Christian Jung, Venet Osmani.

**Investigation:** Raphael Romano Bruno.

**Methodology:** Behrooz Mamandipoor, Georg Wolff, Venet Osmani.

**Project administration:** Christian Jung.

**Resources:** Christian Jung.

**Software:** Behrooz Mamandipoor.

**Supervision:** Christian Jung, Venet Osmani.

**Validation:** Behrooz Mamandipoor, Christian Jung, Venet Osmani.

**Writing – original draft:** Behrooz Mamandipoor, Raphael Romano Bruno, Christian Jung, Venet Osmani.

**Writing – review & editing:** Raphael Romano Bruno, Bernhard Wernly, Georg Wolff, Jesper Fjølner, Antonio Artigas, Bernardo Bollen Pinto, Joerg C. Schefold, Malte Kelm, Michael Beil, Sviri Sigal, Susannah Leaver, Dylan W. De Lange, Bertrand Guidet, Hans Flaatten, Wojciech Szczeklik, Christian Jung, Venet Osmani.

## References

1. Maltese G. et al., “Frailty and COVID-19: A Systematic Scoping Review,” *J Clin Med*, vol. 9, no. 7, p. 2106, Jul. 2020, <https://doi.org/10.3390/jcm9072106> PMID: 32635468
2. Guan W. et al., “Clinical Characteristics of Coronavirus Disease 2019 in China,” *New England Journal of Medicine*, vol. 382, no. 18, pp. 1708–1720, 2020, <https://doi.org/10.1056/NEJMoa2002032> PMID: 32109013
3. Cummings M. J. et al., “Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study,” *The Lancet*, vol. 395, no. 10239, pp. 1763–1770, 2020, [https://doi.org/10.1016/S0140-6736\(20\)31189-2](https://doi.org/10.1016/S0140-6736(20)31189-2) PMID: 32442528
4. Zhou F. et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” *The Lancet*, vol. 395, no. 10229, pp. 1054–1062, 2020, [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3) PMID: 32171076
5. Chang R., Elhusseiny K. M., Yeh Y.-C., and Sun W.-Z., “COVID-19 ICU and mechanical ventilation patient characteristics and outcomes—A systematic review and meta-analysis,” *PLoS One*, vol. 16, no. 2, p. e0246318, Feb. 2021, <https://doi.org/10.1371/journal.pone.0246318> PMID: 33571301
6. Raschke R. A., Agarwal S., Rangan P., Heise C. W., and Curry S. C., “Discriminant Accuracy of the SOFA Score for Determining the Probable Mortality of Patients With COVID-19 Pneumonia Requiring Mechanical Ventilation,” *JAMA*, vol. 325, no. 14, pp. 1469–1470, Apr. 2021, <https://doi.org/10.1001/jama.2021.1545> PMID: 33595630

7. Wynants L. et al., “Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal,” *The BMJ*, vol. 369, 2020, <https://doi.org/10.1136/bmj.m1328> PMID: 32265220
8. Ingraham N. E. et al., “Racial and Ethnic Disparities in Hospital Admissions from COVID-19: Determining the Impact of Neighborhood Deprivation and Primary Language,” *J Gen Intern Med*, vol. 36, no. 11, pp. 3462–3470, Nov. 2021, <https://doi.org/10.1007/s11606-021-06790-w> PMID: 34003427
9. Bruce L. and Tallman R., “Promoting racial equity in COVID-19 resource allocation,” *J Med Ethics*, vol. 47, no. 4, pp. 208–212, Apr. 2021, <https://doi.org/10.1136/medethics-2020-106794> PMID: 33514637
10. Assaf D. et al., “Utilization of machine-learning models to accurately predict the risk for critical COVID-19,” *Intern Emerg Med*, vol. 15, no. 8, pp. 1435–1443, Nov. 2020, <https://doi.org/10.1007/s11739-020-02475-0> PMID: 32812204
11. Gao Y. et al., “Machine learning based early warning system enables accurate mortality risk prediction for COVID-19,” *Nat Commun*, vol. 11, no. 1, p. 5033, Dec. 2020, <https://doi.org/10.1038/s41467-020-18684-2> PMID: 33024092
12. Nafilyan V. et al., “An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England,” *Lancet Digit Health*, vol. 3, no. 7, pp. e425–e433, Jul. 2021, [https://doi.org/10.1016/S2589-7500\(21\)00080-7](https://doi.org/10.1016/S2589-7500(21)00080-7) PMID: 34049834
13. Haimovich A. D. et al., “Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation,” *Ann Emerg Med*, vol. 76, no. 4, pp. 442–453, Oct. 2020, <https://doi.org/10.1016/j.annemergmed.2020.07.022> PMID: 33012378
14. Zheng Y. et al., “A Learning-Based Model to Evaluate Hospitalization Priority in COVID-19 Pandemics,” *Patterns*, vol. 1, no. 6, p. 100092, Sep. 2020, <https://doi.org/10.1016/j.patter.2020.100092> PMID: 32838344
15. Chatterjee A., Wilmink G., Woodruff H., and Lambin P., “Improving and Externally Validating Mortality Prediction Models for COVID-19 Using Publicly Available Data,” *BioMed 2022*, Vol. 2, Pages 13–26, vol. 2, no. 1, pp. 13–26, Jan. 2022, <https://doi.org/10.3390/BIOMED2010002>
16. Roberts M. et al., “Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans,” *Nature Machine Intelligence* 2021 3:3, vol. 3, no. 3, pp. 199–217, Mar. 2021, <https://doi.org/10.1038/s42256-021-00307-0>
17. Chen T. and Guestrin C., “XGBoost: A scalable tree boosting system,” *Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, vol. 13–17-Augu, pp. 785–794, 2016, <https://doi.org/10.1145/2939672.2939785>
18. Neuhaus J. and McCulloch C., “Generalized linear models,” *Wiley Interdiscip Rev Comput Stat*, vol. 3, no. 5, pp. 407–413, 2011, <https://doi.org/10.1002/wics.175>
19. Schwartz-Ziv R. and Armon A., “Tabular data: Deep learning is not all you need,” *Information Fusion*, vol. 81, pp. 84–90, May 2022, <https://doi.org/10.1016/J.INFFUS.2021.11.011>
20. Chicco D. and Jurman G., “The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation,” *BMC Genomics*, vol. 21, no. 1, p. 6, Dec. 2020, <https://doi.org/10.1186/s12864-019-6413-7> PMID: 31898477
21. Carrington A. M. et al., “A new concordant partial AUC and partial c statistic for imbalanced data in the evaluation of machine learning algorithms,” *BMC Med Inform Decis Mak*, vol. 20, no. 1, p. 4, Dec. 2020, <https://doi.org/10.1186/s12911-019-1014-6> PMID: 31906931
22. Carrington A. M. et al., “Deep ROC Analysis and AUC as Balanced Average Accuracy, for Improved Classifier Selection, Audit and Explanation,” *IEEE Trans Pattern Anal Mach Intell*, pp. 1–1, 2022, <https://doi.org/10.1109/TPAMI.2022.3145392> PMID: 35077357
23. Lundberg S. M., Allen P. G., and Lee S.-I., “A Unified Approach to Interpreting Model Predictions”, <https://doi.org/10.5555/3295222>
24. Jung C. et al., “Disease-Course Adapting Machine Learning Prognostication Models in Elderly Patients Critically Ill With COVID-19: Multicenter Cohort Study With External Validation,” *JMIR Med Inform*, vol. 10, no. 3, p. e32949, Mar. 2022, <https://doi.org/10.2196/32949> PMID: 35099394
25. Razavian N. et al., “A validated, real-time prediction model for favorable outcomes in hospitalized COVID-19 patients,” *npj Digital Medicine* 2020 3:1, vol. 3, no. 1, pp. 1–13, Oct. 2020, <https://doi.org/10.1038/s41746-020-00343-x> PMID: 33083565
26. Shashikumar S. P. et al., “Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation,” *Chest*, vol. 159, no. 6, pp. 2264–2273, Jun. 2021, <https://doi.org/10.1016/j.chest.2020.12.009> PMID: 33345948
27. Muller H., Mayrhofer M. T., van Veen E.-B., and Holzinger A., “The Ten Commandments of Ethical Medical AI,” *Computer (Long Beach Calif)*, vol. 54, no. 7, pp. 119–123, Jul. 2021, <https://doi.org/10.1109/MC.2021.3074263>

28. Beil M., Proft I., van Heerden D., Svirid S., and van Heerden P. V., “Ethical considerations about artificial intelligence for prognostication in intensive care,” *Intensive Care Med Exp*, vol. 7, no. 1, 2019, <https://doi.org/10.1186/s40635-019-0286-6> PMID: 31823128
29. Bruno R. R. et al., “Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2860 patients,” *Ann Intensive Care*, vol. 11, no. 1, 2021, <https://doi.org/10.1186/s13613-021-00911-8> PMID: 34417919
30. Jung C. et al., “The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study,” *Crit Care*, vol. 25, no. 1, 2021, <https://doi.org/10.1186/s13054-021-03551-3> PMID: 33874987
31. Bruno R. R. et al., “Early evaluation of organ failure using MELD-XI in critically ill elderly COVID-19 patients,” *Clin Hemorheol Microcirc*, vol. 79, no. 1, pp. 109–120, 2021, <https://doi.org/10.3233/CH-219202> PMID: 34487039
32. Jung C. et al., “Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients,” *Eur Heart J Cardiovasc Pharmacother*, vol. 7, no. 1, pp. 76–77, 2021, <https://doi.org/10.1093/ejhcvp/pvaa083> PMID: 32645153
33. Jung C. et al., “Steroid use in elderly critically ill COVID-19 patients,” *European Respiratory Journal*, vol. 58, no. 4, 2021, <https://doi.org/10.1183/13993003.00979-2021> PMID: 34172464

## S1 Text – Definition of comorbidities

**Diabetes mellitus:** documented evidence of diabetes mellitus or reported by the patient or their relatives. Prescription of anti-diabetic medication or insulin on the drug chart.

**Ischaemic heart disease:** documented abnormal coronary angiography, known coronary artery disease, previous percutaneous coronary intervention (PCI) or coronary bypass surgery


**Chronic renal failure:** documented evidence of chronic renal insufficiency Grade 3 or higher, creatinine clearance <60ml/min or chronic dialysis

**Arterial hypertension:** documented evidence of any grade of chronic arterial hypertension or prescription of anti-hypertensive medication.


**Pulmonary disease:** documented evidence of or medication prescribed for chronic pulmonary disease of any aetiology (bronchial asthma, COPD, pulmonary fibrosis), or clinical or radiological signs of chronic pulmonary disease

**Chronic heart failure:** documented evidence of or medication prescribed for chronic heart failure of any aetiology or echocardiographic or radiological signs of chronic heart failure.


S2 Text – Distribution of length of stay and mortality for the European and non-European cohorts as well as difference between COVID-19 waves



*Fig A Distribution of length of stay (LoS) and mortality rate (in days) for the European cohort, in the left and right panel respectively.*



*Fig B Distribution of length of stay (LoS) and mortality rate (in days) for the non-European cohort, in the left and right panel respectively.*



Source: Johns Hopkins University CSSE COVID-19 Data

CC BY

*Fig C Number of daily confirmed cases per million people, between the first two COVID-19 waves in Europe and France (country with the highest number of ICU admissions in our dataset) from January 28<sup>th</sup>, 2020 (earliest recorded data in the source) up to April 27<sup>th</sup>, 2020 (the end date in our dataset). The first wave peaked around November 7<sup>th</sup>, 2020, and subsided around Dec 1<sup>st</sup>, 2020, which was our cut-off date between the first two waves, to allow us to evaluate the model derived on the patient cohort during the first wave using the patient cohort of the second wave. (Source Our World in Data, John Hopkins University).*

S3 Text – Performance for Area Under the ROC curve, Precision Recall curve as well as model calibration analysis for internal, prospective, and external validation cohorts for each of the outcomes of interest





Fig A Retrospective AUC (top row) and AUPRC (bottom row) performance of each model in internal cross-validation (top panel) and external validation on patients admitted in ICUs in France as the country with the highest number of ICU admissions (bottom panel) for each of the three outcomes.

### ICU Mortality


### 30 day mortality

### Low-risk prediction

Model derivation performance (cross-validation)



Model validation performance on the cohort admitted after the cut-off date



**Fig B** Prospective AUC (top row) and AUPRC (bottom row) performance of each model in internal cross-validation (top) of the cohort of patients admitted to ICUs from January 11, 2020, until the cut-off date of December 1<sup>st</sup>, 2020 (top).


Prospective validation on the cohort of patients admitted to ICUs after the cut-off date until April 27, 2021 (bottom) for each of the three outcomes.

ICU Mortality

30 day mortality

Low-risk prediction

## Model derivation performance of the European cohort (cross-validation)



## Model validation performance on the non European cohort







Fig C AUC (top row) and AUPRC (bottom row) performance of cross validation of the model derived on the overall European cohort (top panel) and its external validation in a cohort of Asian, African and American patients (bottom panel) for each of the three outcomes.



*Fig D Calibration quality of each model in internal cross-validation (top) and external validation on France as the country with the highest number of ICU admissions (bottom) for each of the three outcomes.*



*Fig E Calibration quality of each model in internal cross-validation (top) of the cohort of patients admitted to ICUs from January 11, 2020, until the cut-off date of December 1st, 2020 (top). Prospective validation on the cohort of patients admitted to ICUs after the cut-off date until April 27, 2021 (bottom) for each of the three outcomes.*



*Fig F Calibration quality of cross validation of the overall European cohort (top) and external validation of the model in a cohort of Asian, African and American patients (bottom) for each of the three outcomes.*

S4 Text - Detailed performance metrics, including Average Precision, Positive and Negative Predictive Value, F-1 score, Mathews Correlation Coefficient as well as Brier calibration score, for the internal, prospective, and the external validation cohorts for each of the outcomes of interest

#### Retrospective evaluation of European cohort

<b>ICU</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.76 [0.76-0.77]	0.72 [0.71-0.73]	0.67 [0.65-0.68]	0.71 [0.70-0.71]	0.66 [0.65-0.67]	0.37 [0.36-0.39]	0.20 [0.19-0.20]
<b>FF</b>	0.77 [0.76-0.78]	0.72 [0.71-0.73]	0.66 [0.65-0.67]	<b>0.73</b> [0.72-0.74]	<b>0.68</b> [0.67-0.69]	0.39 [0.38-0.41]	0.20 [0.20-0.20]
<b>Xgb</b>	<b>0.79</b> [0.78-0.79]	<b>0.76</b> [0.75-0.76]	<b>0.68</b> [0.67-0.69]	<b>0.73</b> [0.73-0.74]	<b>0.68</b> [0.68-0.69]	<b>0.41</b> [0.40-0.42]	<b>0.19</b> [0.19-0.19]

<b>30-day</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.75 [0.74-0.76]	0.72 [0.71-0.73]	0.67 [0.66-0.68]	0.70 [0.70-0.70]	0.66 [0.65-0.66]	0.37 [0.36-0.37]	0.20 [0.20-0.21]
<b>FF</b>	0.75 [0.75-0.76]	0.72 [0.71-0.73]	0.66 [0.65-0.67]	<b>0.72</b> [0.72-0.73]	<b>0.68</b> [0.67-0.68]	0.38 [0.37-0.39]	0.20 [0.20-0.21]
<b>Xgb</b>	<b>0.77</b> [0.77-0.78]	<b>0.76</b> [0.75-0.76]	<b>0.69</b> [0.68-0.70]	0.71 [0.71-0.72]	0.67 [0.67-0.68]	<b>0.40</b> [0.38-0.41]	<b>0.19</b> [0.19-0.20]

<b>Low risk</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.85 [0.84-0.86]	0.48 [0.46-0.50]	0.44 [0.39-0.49]	0.92 [0.92-0.92]	0.43 [0.41-0.45]	0.36 [0.34-0.39]	0.10 [0.09-0.10]
<b>FF</b>	0.85 [0.84-0.87]	<b>0.50</b> [0.48-0.52]	<b>0.51</b> [0.48-0.54]	0.92 [0.92-0.92]	0.42 [0.40-0.44]	0.37 [0.35-0.39]	<b>0.09</b> [0.08-0.09]
<b>Xgb</b>	<b>0.86</b> [0.85-0.87]	0.49 [0.47-0.51]	0.44 [0.42-0.47]	<b>0.93</b> [0.93-0.93]	<b>0.44</b> [0.43-0.45]	<b>0.37</b> [0.36-0.38]	0.10 [0.09-0.10]

#### External validation on the French cohort

<b>ICU</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.80	0.70	0.65	0.75	0.63	0.40	0.18

	[0.80-0.80]	[0.70-0.70]	[0.64-0.65]	[0.75-0.76]	[0.63-0.64]	[0.39-0.40]	[0.18-0.18]
<b>FF</b>	0.80 [0.80-0.80]	0.70 [0.70-0.71]	0.66 [0.66-0.67]	0.79 [0.79-0.80]	0.68 [0.68-0.69]	0.46 [0.46-0.47]	0.18 [0.18-0.18]
<b>Xgb</b>	<b>0.82</b> [0.82-0.82]	<b>0.73</b> [0.72-0.73]	<b>0.67</b> [0.66-0.67]	<b>0.80</b> [0.80-0.80]	<b>0.69</b> [0.69-0.69]	<b>0.47</b> [0.47-0.48]	<b>0.17</b> [0.17-0.17]

<b>30-day</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.77 [0.76-0.77]	0.66 [0.66-0.66]	0.60 [0.60-0.60]	0.76 [0.76-0.77]	0.63 [0.63-0.63]	0.37 [0.37-0.37]	<b>0.19</b> [0.19-0.20]
<b>FF</b>	0.77 [0.77-0.77]	0.66 [0.66-0.66]	0.59 [0.59-0.60]	<b>0.79</b> [0.79-0.80]	0.65 [0.65-0.66]	0.39 [0.39-0.40]	0.20 [0.20-0.20]
<b>Xgb</b>	<b>0.79</b> [0.79-0.79]	<b>0.68</b> [0.68-0.68]	<b>0.64</b> [0.63-0.64]	<b>0.79</b> [0.79-0.79]	<b>0.67</b> [0.67-0.67]	<b>0.44</b> [0.43-0.44]	<b>0.19</b> [0.19-0.19]

<b>Low risk</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	<b>0.86</b> [0.85-0.86]	0.50 [0.50-0.51]	0.55 [0.54-0.55]	0.87 [0.87-0.87]	0.48 [0.47-0.49]	0.38 [0.38-0.39]	0.12 [0.12-0.12]
<b>FF</b>	0.85 [0.85-0.85]	0.51 [0.50-0.51]	0.55 [0.55-0.56]	0.85 [0.85-0.86]	0.39 [0.38-0.39]	0.31 [0.31-0.32]	0.12 [0.12-0.12]
<b>Xgb</b>	<b>0.86</b> [0.86-0.87]	<b>0.54</b> [0.54-0.55]	<b>0.57</b> [0.56-0.57]	<b>0.88</b> [0.88-0.88]	<b>0.50</b> [0.50-0.51]	<b>0.41</b> [0.40-0.42]	<b>0.11</b> [0.11-0.11]

Prospective evaluation performance of the European cohort in internal cross-validation

<b>ICU</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.76 [0.76-0.77]	0.68 [0.67-0.69]	0.64 [0.64-0.65]	0.74 [0.73-0.74]	0.64 [0.64-0.65]	0.38 [0.37-0.39]	0.20 [0.19-0.20]
<b>FF</b>	0.76 [0.76-0.77]	0.68 [0.67-0.69]	0.65 [0.64-0.66]	0.73 [0.73-0.74]	0.64 [0.63-0.65]	0.38 [0.37-0.39]	0.20 [0.19-0.20]
<b>Xgb</b>	<b>0.79</b> [0.79-0.80]	<b>0.72</b> [0.71-0.72]	<b>0.67</b> [0.66-0.68]	<b>0.75</b> [0.74-0.75]	<b>0.66</b> [0.65-0.66]	<b>0.41</b> [0.40-0.43]	<b>0.18</b> [0.18-0.18]

<b>30-day</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.75 [0.75-0.76]	0.67 [0.66-0.68]	0.65 [0.64-0.67]	0.72 [0.71-0.73]	0.61 [0.60-0.62]	0.37 [0.35-0.39]	0.20 [0.20-0.20]

<b>FF</b>	0.75 [0.75-0.76]	0.67 [0.66-0.68]	0.63 [0.62-0.64]	<b>0.74</b> [0.74-0.75]	0.64 [0.63-0.65]	0.38 [0.36-0.39]	0.20 [0.20-0.20]
<b>Xgb</b>	<b>0.77</b> [0.77-0.78]	<b>0.70</b> [0.69-0.72]	<b>0.66</b> [0.65-0.67]	<b>0.74</b> [0.73-0.75]	<b>0.63</b> [0.62-0.64]	<b>0.39</b> [0.37-0.41]	<b>0.19</b> [0.19-0.19]

<b>Low risk</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.84 [0.83-0.85]	0.47 [0.45-0.48]	0.45 [0.43-0.46]	0.90 [0.90-0.90]	0.42 [0.42-0.43]	0.34 [0.33-0.35]	0.11 [0.11-0.11]
<b>FF</b>	0.85 [0.85-0.86]	0.49 [0.47-0.51]	<b>0.64</b> [0.60-0.68]	0.90 [0.90-0.90]	0.36 [0.34-0.39]	0.35 [0.33-0.37]	<b>0.09</b> [0.09-0.09]
<b>Xgb</b>	<b>0.87</b> [0.86-0.87]	<b>0.51</b> [0.49-0.53]	0.47 [0.45-0.50]	<b>0.92</b> [0.92-0.92]	<b>0.48</b> [0.46-0.49]	<b>0.40</b> [0.38-0.42]	0.10 [0.09-0.10]

Prospective evaluation on the cohort of patients admitted after the cut-off date

<b>ICU</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.82 [0.82-0.82]	0.81 [0.81-0.81]	0.77 [0.77-0.77]	0.72 [0.72-0.72]	0.75 [0.75-0.75]	0.49 [0.49-0.50]	<b>0.17</b> [0.17-0.17]
<b>FF</b>	0.82 [0.82-0.82]	0.81 [0.81-0.81]	0.77 [0.77-0.77]	0.72 [0.71-0.72]	0.75 [0.74-0.75]	0.48 [0.48-0.49]	0.18 [0.18-0.18]
<b>Xgb</b>	<b>0.83</b> [0.83-0.83]	<b>0.82</b> [0.82-0.82]	<b>0.78</b> [0.77-0.78]	<b>0.73</b> [0.72-0.73]	<b>0.76</b> [0.76-0.76]	<b>0.50</b> [0.50-0.50]	<b>0.17</b> [0.17-0.17]

<b>30-day</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.77 [0.77-0.77]	0.80 [0.80-0.80]	<b>0.78</b> [0.78-0.78]	0.62 [0.61-0.62]	0.69 [0.69-0.69]	0.39 [0.39-0.40]	0.20 [0.20-0.21]
<b>FF</b>	0.77 [0.77-0.78]	<b>0.81</b> [0.80-0.81]	0.76 [0.76-0.76]	<b>0.65</b> [0.65-0.66]	<b>0.73</b> [0.72-0.73]	<b>0.41</b> [0.41-0.42]	0.20 [0.19-0.20]
<b>Xgb</b>	0.77 [0.77-0.77]	<b>0.81</b> [0.81-0.81]	<b>0.78</b> [0.77-0.78]	0.62 [0.62-0.63]	0.70 [0.70-0.70]	0.40 [0.40-0.41]	0.20 [0.20-0.20]

<b>Low risk</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.84 [0.84-0.84]	0.41 [0.41-0.41]	0.39 [0.39-0.40]	0.92 [0.92-0.92]	0.45 [0.44-0.45]	0.36 [0.35-0.36]	0.13 [0.13-0.13]
<b>FF</b>	<b>0.85</b> [0.85-0.85]	0.44 [0.43-0.44]	<b>0.47</b> [0.46-0.48]	0.91 [0.91-0.91]	0.40 [0.39-0.42]	0.34 [0.33-0.35]	<b>0.10</b> [0.10-0.10]

<b>Xgb</b>	<b>0.85</b> [0.85-0.85]	<b>0.47</b> [0.46-0.47]	0.40 [0.39-0.41]	<b>0.93</b> [0.93-0.93]	<b>0.46</b> [0.45-0.46]	<b>0.37</b> [0.36-0.38]	0.11 [0.11-0.11]
------------	----------------------------	----------------------------	---------------------	----------------------------	----------------------------	----------------------------	---------------------

Internal cross-validation of the overall European cohort

<b>ICU</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.78 [0.77-0.79]	0.73 [0.72-0.73]	<b>0.68</b> [0.67-0.69]	0.74 [0.73-0.75]	0.68 [0.67-0.69]	0.42 [0.41-0.43]	0.19 [0.19-0.19]
<b>FF</b>	0.78 [0.77-0.79]	0.72 [0.71-0.73]	0.65 [0.64-0.66]	<b>0.77</b> [0.76-0.77]	<b>0.69</b> [0.69-0.70]	0.42 [0.40-0.43]	0.20 [0.19-0.20]
<b>Xgb</b>	<b>0.81</b> [0.80-0.81]	<b>0.75</b> [0.75-0.76]	<b>0.68</b> [0.67-0.69]	0.75 [0.75-0.76]	<b>0.69</b> [0.69-0.69]	<b>0.43</b> [0.42-0.44]	<b>0.18</b> [0.18-0.18]

<b>30-day</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.76 [0.76-0.77]	0.71 [0.71-0.72]	<b>0.68</b> [0.67-0.69]	0.71 [0.70-0.71]	0.65 [0.64-0.65]	0.38 [0.37-0.39]	0.20 [0.20-0.20]
<b>FF</b>	0.76 [0.76-0.77]	0.71 [0.70-0.72]	0.66 [0.65-0.67]	<b>0.73</b> [0.72-0.73]	0.66 [0.65-0.67]	0.38 [0.37-0.39]	0.20 [0.20-0.20]
<b>Xgb</b>	<b>0.78</b> [0.77-0.78]	<b>0.74</b> [0.73-0.74]	<b>0.68</b> [0.67-0.69]	<b>0.73</b> [0.73-0.74]	<b>0.68</b> [0.67-0.68]	<b>0.41</b> [0.40-0.42]	<b>0.19</b> [0.19-0.19]

<b>Low risk</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.86 [0.85-0.87]	0.50 [0.48-0.53]	0.49 [0.46-0.51]	<b>0.92</b> [0.92-0.93]	0.48 [0.46-0.50]	0.40 [0.38-0.43]	0.10 [0.09-0.10]
<b>FF</b>	0.85 [0.84-0.87]	0.51 [0.48-0.53]	0.51 [0.47-0.54]	0.91 [0.91-0.92]	0.45 [0.43-0.47]	0.38 [0.35-0.41]	0.10 [0.09-0.10]
<b>Xgb</b>	<b>0.87</b> [0.86-0.88]	<b>0.52</b> [0.49-0.54]	<b>0.52</b> [0.48-0.55]	<b>0.92</b> [0.92-0.93]	<b>0.49</b> [0.47-0.51]	<b>0.42</b> [0.40-0.45]	0.10 [0.09-0.10]

External validation of the European cohort on the patients from non-European ICUs


<b>ICU</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.84 [0.84-0.84]	0.84 [0.84-0.84]	0.82 [0.82-0.82]	0.65 [0.65-0.65]	0.70 [0.69-0.70]	0.46 [0.45-0.46]	0.18 [0.18-0.18]
<b>FF</b>	0.84 [0.84-0.85]	0.84 [0.84-0.85]	0.81 [0.81-0.82]	<b>0.71</b> [0.70-0.72]	0.76 [0.76-0.77]	0.52 [0.52-0.53]	0.17 [0.17-0.17]

<b>Xgb</b>	<b>0.89</b> [0.89-0.89]	<b>0.88</b> [0.88-0.88]	<b>0.84</b> [0.84-0.85]	<b>0.71</b> [0.71-0.72]	<b>0.77</b> [0.76-0.77]	<b>0.55</b> [0.55-0.56]	<b>0.15</b> [0.15-0.15]
------------	----------------------------	----------------------------	----------------------------	----------------------------	----------------------------	----------------------------	----------------------------

<b>30-day</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.83 [0.83-0.83]	0.85 [0.85-0.85]	<b>0.82</b> [0.82-0.82]	0.68 [0.67-0.68]	0.74 [0.73-0.74]	0.50 [0.49-0.50]	0.17 [0.17-0.18]
<b>FF</b>	0.83 [0.83-0.83]	0.84 [0.84-0.84]	0.81 [0.80-0.81]	0.72 [0.71-0.72]	0.77 [0.77-0.77]	<b>0.53</b> [0.52-0.53]	0.17 [0.17-0.17]
<b>Xgb</b>	<b>0.86</b> [0.86-0.86]	<b>0.87</b> [0.86-0.87]	0.81 [0.80-0.81]	<b>0.74</b> [0.74-0.74]	<b>0.79</b> [0.78-0.79]	0.55 [0.54-0.55]	<b>0.16</b> [0.15-0.16]

<b>Low risk</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>LR</b>	0.85 [0.85-0.85]	0.59 [0.59-0.60]	0.64 [0.63-0.64]	<b>0.80</b> [0.80-0.80]	<b>0.42</b> [0.41-0.43]	<b>0.33</b> [0.33-0.34]	0.15 [0.15-0.15]
<b>FF</b>	0.85 [0.85-0.85]	0.58 [0.58-0.58]	0.64 [0.63-0.64]	0.79 [0.79-0.80]	0.39 [0.38-0.40]	0.31 [0.31-0.32]	<b>0.14</b> [0.14-0.14]
<b>Xgb</b>	<b>0.86</b> [0.86-0.86]	<b>0.63</b> [0.62-0.63]	<b>0.68</b> [0.67-0.69]	0.79 [0.79-0.79]	0.37 [0.36-0.39]	0.32 [0.31-0.33]	<b>0.14</b> [0.14-0.14]

## S5 Text – Variable ranking for the European and non-European cohort for each of the three outcomes of interest



*Fig A Variable ranking based on average SHAP values for each of the three outcomes for the model derived in the overall European cohort and validated in the external, non-European cohort.*

S6 Text – Evaluation of generalisability of the model derived on the European cohort using each of the top-9 European countries (based on the number of ICU admissions) as the test cohort.

*Table A Model performance in predicting 30-day mortality in the European cohort of patients, evaluated on a single European country (shown in the first column based on ISO 3166-1, while England is represented as EN) and derived on the remaining European countries. Country and territory abbreviations are detailed in Appendix 9.*

<b>30-day</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>FR</b>	0.79	0.68	0.63	0.78	0.66	0.42	0.19
<b>ES</b>	0.71	0.68	0.66	0.65	0.55	0.29	0.22
<b>NL</b>	0.74	0.64	0.60	0.73	0.58	0.32	0.20
<b>DE</b>	0.75	0.66	0.59	0.79	0.65	0.38	0.21
<b>CH</b>	0.79	0.77	0.70	0.73	0.70	0.42	0.19
<b>DK</b>	0.74	0.69	0.64	0.69	0.56	0.31	0.20
<b>BE</b>	0.83	0.78	0.79	<b>0.79</b>	0.67	<b>0.54</b>	<b>0.16</b>
<b>EN</b>	<b>0.84</b>	<b>0.91</b>	<b>0.94</b>	0.55	<b>0.75</b>	0.52	0.20
<b>GR</b>	0.80	0.83	0.75	0.67	0.73	0.41	0.18

*Table B Model performance in predicting ICU mortality in the European cohort of patients, evaluated on a single European country (shown in the first column based on ISO 3166-1) and derived on the remaining European countries. Country and territory abbreviations are detailed in Appendix 9.*

<b>ICU</b>	<b>AUC</b>	<b>AP</b>	<b>PPV</b>	<b>NPV</b>	<b>F-1</b>	<b>MCC</b>	<b>Brier</b>
<b>FR</b>	0.82	0.73	0.68	0.80	0.70	0.49	0.17
<b>ES</b>	0.71	0.69	0.70	0.62	0.61	0.32	0.22
<b>NL</b>	0.77	0.67	0.62	0.74	0.59	0.35	0.19
<b>DE</b>	0.83	0.80	0.66	0.80	0.72	0.47	0.17
<b>CH</b>	0.72	0.57	0.56	0.77	0.62	0.33	0.21
<b>DK</b>	0.82	0.74	0.67	0.82	0.69	0.49	0.18
<b>BE</b>	<b>0.91</b>	0.84	0.77	<b>0.85</b>	0.73	<b>0.60</b>	<b>0.13</b>
<b>EN</b>	0.86	0.89	<b>0.87</b>	0.67	0.77	0.54	0.17
<b>GR</b>	0.81	<b>0.90</b>	0.84	0.64	<b>0.83</b>	0.49	0.18

*Table C Model performance in predicting low-risk patients in the European cohort, evaluated on a single European country (shown in the first column based on ISO 3166-1) and derived on the remaining European countries. Country and territory abbreviations are detailed in Appendix 9.*

Low risk	AUC	AP	PPV	NPV	F-1	MCC	Brier
<b>FR</b>	0.86	0.53	0.56	0.86	0.42	0.34	0.11
<b>ES</b>	0.85	0.38	0.30	0.96	0.32	0.27	<b>0.08</b>
<b>NL</b>	0.83	0.34	0.30	0.95	0.40	0.33	0.12
<b>DE</b>	0.91	0.62	0.51	0.95	0.56	<b>0.50</b>	0.10
<b>CH</b>	<b>0.92</b>	0.56	0.28	<b>0.98</b>	0.40	0.38	0.09
<b>DK</b>	0.75	0.37	0.39	0.87	0.28	0.20	0.13
<b>BE</b>	0.80	0.67	<b>0.74</b>	0.66	0.35	0.27	0.18
<b>EN</b>	0.90	<b>0.68</b>	0.37	0.97	0.49	0.45	0.13
<b>PT*</b>	0.82	0.57	0.52	0.90	<b>0.58</b>	0.46	0.16

\*Since there were no patients in the Greek (GR) cohort that met the criteria for low-risk patients, we considered the next available country, which was Portugal (PT).

S7 Text – Patients' characteristics, including differences between the full set of variables, for the European and non-European cohort with respect to the three outcomes of interest (ICU and 30-day mortality and prediction of low-risk patients)

*Table A Patients' characteristics for the European and non-European cohort with respect to 30-day mortality*


30-day mortality	European			Non-European		
Variable	Alive	Dead	p-value	Alive	Dead	p-value
Patients	1568	1290	-	281	335	-
Age (year)	74 [72,77]	76 [73,79]	<0.001	75 [72,80]	77 [73,83]	<0.001
Sex (Female)	452 (28.8)	375 (29.1)	0.919	114 (40.6)	130 (38.8)	0.717
Weight (kg)	81 [72,91]	80 [72,90]	0.041	78 [69.8,90]	78 [70,87]	0.708
Height (cm)	171 [165,178]	170 [164,176]	0.017	165 [159,170]	166 [160,173]	0.142
BMI	27.7 [24.8,30.9]	27.5 [24.7,30.9]	0.427	27.9 [25.0,33.2]	28.3 [25.6,31.1]	0.722
SOFA overall score	4 [3,7]	6 [4,9]	<0.001	4 [2,5]	7 [5,10]	<0.001
Presence of diabetes	481 (30.8)	471 (36.7)	0.001	149 (53.2)	194 (58.4)	0.225
Ischemic heart disease	299 (19.3)	327 (25.6)	<0.001	77 (27.6)	93 (28.6)	0.852
Renal comorbidity	175 (11.2)	273 (21.3)	<0.001	29 (10.4)	80 (24.3)	<0.001
Arterial hypertension	1025 (65.6)	861 (66.9)	0.483	172 (61.6)	235 (71.0)	0.019
Pulmonary disease	337 (21.5)	305 (23.8)	0.164	45 (16.1)	61 (18.8)	0.457
Congestive heart failure	178 (11.5)	230 (18.1)	<0.001	32 (11.6)	49 (14.9)	0.286
Mechanical ventilation	1057 (67.4)	1064 (82.5)	<0.001	69 (24.6)	271 (80.9)	<0.001
Vasopressors	997 (63.6)	1085 (84.1)	<0.001	37 (13.2)	185 (55.2)	<0.001
Renal replacement therapy	180 (11.5)	282 (21.9)	<0.001	17 (6.0)	51 (15.2)	<0.001
Non-invasive ventilation	401 (25.6)	344 (26.7)	0.536	73 (26.0)	157 (46.9)	<0.001
Tracheostomy	378 (24.1)	161 (12.5)	<0.001	17 (6.0)	10 (3.0)	0.098
ICU LoS (day)	15 [7,32]	11 [6,17]	<0.001	6 [4,10]	7 [4,10]	0.767

**Table B Patients' characteristics for the European and non-European cohort with respect to identifying low-risk patients**

Low-risk	European				non-European			
Variable	Low risk	High risk (survivors )	High risk (non- survivors )	p- value	Low risk	Alive	Dead	p- value

Patients	371	1203	1284	-	157	127	332	-
<b>Age (year)</b>	75 [72.5,79]	74 [72,77]	75 [72,79]	<0.001	76 [73,80]	75 [72,80]	77 [73,83]	0.006
<b>Sex (Female)</b>	116 (31.3)	361 (30.0)	350 (27.3)	0.182	65 (41.4)	50 (39.4)	129 (38.9)	0.864
<b>Weight (kg)</b>	80 [70,90]	81 [72,91]	80 [72,90]	0.016	80 [67,95.5]	77 [70,85]	78 [70,87]	0.424
<b>Height (cm)</b>	170 [164,176]	170 [165,178]	170 [165,177]	0.087	160 [154,166]	167 [160,172]	166 [160,173]	<0.001
<b>BMI</b>	27.1 [24.2,30.5]	27.7 [25,31]	27.5 [24.7,30.8]	0.1	31.2 [25.6,38]	27.4 [24.8,30.5]	28.3 [25.6,31.1]	0.003
<b>SOFA overall score</b>	3 [2,4]	5 [3,8]	6 [4,9]	<0.001	3 [2,4]	5 [3,8]	7 [5,10]	<0.001
<b>Presence of diabetes</b>	113 (30.6)	377 (31.4)	462 (36.2)	0.02	87 (55.4)	69 (54.8)	187 (56.8)	0.908
<b>Ischemic heart disease</b>	90 (24.3)	228 (19.2)	308 (24.3)	0.005	39 (24.8)	39 (31.2)	92 (28.6)	0.484
<b>Renal comorbidity</b>	51 (13.8)	142 (11.8)	255 (20.0)	<0.001	5 (3.2)	24 (19.2)	80 (24.5)	<0.001
<b>Arterial hypertension</b>	248 (67.2)	781 (65.1)	857 (66.9)	0.572	87 (55.4)	87 (69.0)	233 (71.3)	0.002
<b>Pulmonary disease</b>	83 (22.4)	258 (21.5)	301 (23.6)	0.442	21 (13.4)	26 (20.6)	59 (18.4)	0.238
<b>Congestive heart failure</b>	54 (14.7)	149 (12.5)	205 (16.2)	0.032	14 (9.0)	19 (15.3)	48 (14.8)	0.169
<b>ICU LoS (day)</b>	5 [2,7.5]	16 [8,31]	14 [7,22]	<0.001	5 [3,9]	8 [4.5,15]	7 [4,11]	<0.001

## S8 Text – Cohort selection diagram



## S9 Text – Abbreviations of the countries and territories

<b>AT</b>	Austria	<b>LY</b>	Libya
<b>BE</b>	Belgium	<b>MA</b>	Morocco
<b>CH</b>	Switzerland	<b>MX</b>	Mexico
<b>CO</b>	Colombia	<b>NL</b>	Netherlands
<b>DE</b>	Germany	<b>NO</b>	Norway
<b>DK</b>	Denmark	<b>OM</b>	Oman
<b>EG</b>	Egypt	<b>PS</b>	Palestine
<b>EN</b>	England (UK)	<b>PK</b>	Pakistan
<b>ES</b>	Spain	<b>PO</b>	Poland
<b>FR</b>	France	<b>PS</b>	Palestine
<b>GR</b>	Greece	<b>PT</b>	Portugal
<b>IE</b>	Ireland	<b>RO</b>	Romania
<b>IL</b>	Israel	<b>SA</b>	Saudi Arabia
<b>IN</b>	India	<b>SD</b>	Sudan
<b>IQ</b>	Iraq	<b>SY</b>	Syrian Arab Republic
<b>IR</b>	Iran	<b>TR</b>	Turkey
<b>IT</b>	Italy	<b>US</b>	United States of America
<b>JO</b>	Jordan	<b>WL</b>	Wales (UK)
<b>LB</b>	Lebanon	<b>YE</b>	Yemen